Pharmacological aspects of Vipera xantina palestinae venom

Toxins

Volumn 3, Issue 11, 2011, Pages 1420-1432

  Momic, Tatjana ^a   Arlinghaus, Franziska T ^b   Arien Zakay, Hadar ^a   Katzhendler, Jeoshua ^a   Eble, Johannes A ^b   Marcinkiewicz, Cezary ^c   Lazarovici, Philip ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Antivenom; Hemorrhagin; Integrin inhibitors; Neurotoxin; Venom; Vipera xantina palestinae

Indexed keywords

ANGIONEURIN GROWTH FACTOR; DISINTEGRIN; GROWTH FACTOR; HEMORRHAGIN; INTEGRIN INHIBITOR; LECTIN; NEUROTOXIN; OBTUSTATIN; SNAKE VENOM; SNAKE VENOM ANTISERUM; UNCLASSIFIED DRUG; VIPERISTATIN; VP12;

AMINO ACID SEQUENCE; ENVENOMATION; HUMAN; NONHUMAN; POISONOUS SNAKE; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SEQUENCE HOMOLOGY; UNSPECIFIED SIDE EFFECT; VIPERA XANTINA PALESTINAE;

ANIMALS; ANTIVENINS; HUMANS; INTEGRINS; NERVE GROWTH FACTOR; NEUROTOXINS; PROTEOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIPER VENOMS; VIPERIDAE;

EID: 82255170992     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins3111420     Document Type: Review

References (64)

1. Paret, G.; Ben-Abraham, R.; Ezra, D.; Shrem, D.; Eshel, G.; Vardi, A.; Winkler, E.; Barzilay, Z. Vipera palaestinae snake envenomations: Experience in children. Hum. Exp. Toxicol. 1997, 16, 683-687.
2. Coppola, M.; Hogan, D.E. Venomous snakes of south-west Asia. Am. J. Emerg. Med. 1992, 10, 230-236.
3. Mendelssohn, H. On the biology of venomous snakes of Israel. Isr. J. Zool. 1963, 12, 143-170.
4. Thwin, M.-M.; Gopalakrishnakone, P. Snake envenomation and protective natural endogenous proteins: A mini review of the recent developments (1991-1997). Toxicon 1998, 36, 1471-1482
5. Winkler, E.; Chovers, M.; Almog, S.; Pri-Chen, S.; Rotenberg, M.; Tirosh, M.; Ezra, D.; Halkin, H. Decreased serum cholesterol level after snake bite (Vipera palestinae) as a marker of severity of envenomation. J. Lab. Clin. Med. 1993, 121, 774-778.
6. Bentur, Y.; Raikhlin-Eisenkraft, B.; Galperin, M. Evaluation of antivenom therapy in Vipera palaestinae bites. Toxicon 2004, 44, 53-57.
7. Aroch, I.; Harrus, S. Retrospective study of the epidemiological, clinical, haematological and biochemical findings in 109 dogs poisoned by Vipera xanthina palestinae. Vet. Rec. 1999, 144, 532-535.
8. Gitter, S.; de Vries, A. Symptomatology, Pathology and Treatment of Bites by Near Eastern, European and North African Snakes. In Animals and Their Venoms; Bucherl, W., Buckley, E.E., Deulofeu, V., Eds.; Academic Press: New York, NY, USA, 1968; pp. 359-401.
9. Moroz-Perlmutter, C.; Goldblum, N.; de Vries, A. Biochemical and antigenic properties of a purified neurotoxin of Vipera palestinae venom. J. Immunol. 1965, 94, 164-171.
10. Ovadia, M.; Kochva, E.; Moav, B. Purification and partial characterization of lethal synergistic components from the venom of Vipera palaestinae. Toxicon 1977, 15, 549-560.
11. Simon, T.; Bdolah, A.; Kochva, E. The two-component toxin of Vipera palaestinae: Contribution of phospholipase A to its activity. Toxicon 1980, 18, 249-259.
12. Krizaj, I.; Bdolah, A.; Gubensek, F.; Bencina, P.; Pungercar, J. Protein and cDNA structures of an acidic phospholipase A2, the enzymatic part of an unusual, two-component toxin from Vipera palaestinae. Biochem. Biophys. Res. Commun. 1996, 227, 374-379.
13. Grotto, L.; Jerushalmy, Z.; de Vries, A. Effect of purified Vipera paletinae hemorrhagin on blood coagulation and platelet function. Thromb. Diath. Haemorrh. 1969, 22, 482-495.
14. Grotto, L.; Moroz, C.; de Vries, A.; Goldblum, N. Isolation of Vipera palestinae hemorrhagin and distinction between its hemorrhagic and proteolytic activities. Biochim. Biophys. Acta 1967, 133, 356-362.
15. Ovadia, M. Isolation and characterization of three hemorrhagic factors from the venom of Vipera palaestinae. Toxicon 1978, 16, 479-487.
16. Nakar, O.; Ovadia, M.; Kochva, E. Isolation and characterization of a proteolytic factor from the venom of Vipera palaestinae. Toxicon 1986, 24, 293-304.
17. UniProtKB/Swiss-Prot v56.5. Available online: http://us.expasy.org/sprot/ (accessed on 11 November 2011)
18. Brown, M.C.; Calvete, J.J.; Staniszewska, I.; Walsh, E.M.; Georgina, P.-L.; Dell Valle, L.; Lazarovici, P.; Marcinkiewicz, C. VEGF-related protein isolated from Vipera palestinae venom, promotes angiogenesis. Growth Factors 2007, 25, 108-117.
19. Kostiza, T.; Dahinden, C.A.; Rihs, S.; Otten, U.; Meier, J. Nerve growth factor from the venom of the Chinese cobra Naja naja atra: Purification and description of non-neuronal activities. Toxicon 1995, 33, 1249-1261.
20. Weis, S.M.; Cheresh, D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005, 437, 497-504.
21. Kisiel, D.G.; Calvete, J.J.; Katzhendler, J.; Fertala, A.; Lazarovici, P.; Marcinkiewicz, C. Structural determinants of the selectivity of KTS-disintegrins for the α1β1 integrin. FEBS Lett. 2004, 577, 478-482.
22. Calvete, J.J.; Juárez, P.; Sanz, L. Snake venomics. Strategy and applications. J. Mass Spectrom. 2007, 42, 1405-1414.
23. Yamazaki, Y.; Morita, T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Divers. 2006, 10, 515-527.
24. Yamane, A.; Seetharam, L.; Yamaguchi, S.; Gotoh, N.; Takahashi, T.; Neufeld, G.; Shibuya, M. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994, 9, 2683-2690.
25. de Vries, C.; Escobedo, J.A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
26. Terman, B.I.; Dougher-Vermazen, M.; Carrion, M.E.; Dimitrov, D.; Armellino, D.C.; Gospodarowicz, D.; Böhlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
27. Quinn, T.P.; Peters, K.G.; de Vries, C.; Ferrara, N.; Williams, L.T. Fet-aletal /et-alliver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. USA 1993, 90, 7533-7537.
28. Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E.; Saksela, O.; Kalkkinen, N.; Alitalo, K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15, 290-298.
29. Lee, J.; Gray, A.; Yuan, J.; Luoh, S.M.; Avraham, H.; Wood, W.I. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA 1996, 93, 1988-1992.
30. Achen, M.G.; Jeltsch, M.; Kukk, E.; Makinen, T.; Vitali, A.; Wilks, A.F.; Alitalo, K.; Stacker, S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 1998, 95, 548-553.
31. Soker, S.; Takashima, S.; Miao, H.Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92, 735-745.
32. Gluzman-Poltorak, Z.; Cohen, T.; Herzog, Y.; Neufeld, G. europilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth actor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J. Biol. Chem. 2000, 275, 18040-18045.
33. Yamazaki, Y.; Takani, K.; Atoda, H.; Morita, T. Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF Receptor 2). J. Biol. Chem. 2003, 278, 51985-51988.
34. Paalme, V.; Trummal, K.; Samel, M.; Tõnismägi, K.; Järvekülg, L.; Vija, H.; Subbi, J.; Siigur, J.; Siigur, E. Nerve growth factor from Vipera lebetina venom. Toxicon 2009, 54, 329-336.
35. Levi-Montalcini, R. The nerve growth factor 35 years later. Science 1987, 237, 1154-1162.
36. Kaplan, D.R.; Miller, F.D. Signal transduction by the neutrophin receptors. Curr. Opin. Cell Biol. 1997, 9, 213-221.
37. Selby, M.J.; Edwards, R.H.; Rutter, W.J. Cobra nerve growth factor: Structure and evolutionary comparison. J. Neurosci. Res. 1987, 18, 293-298.
38. Siigur, E.; Neuman, T.; Järve, V.; Tara, A.; Siigur, J. Isolation and characterization of nerve growth factor from Vipera lebetina (snake) venom. Comp. Biochem. Physiol. B 1985, 81, 211-215.
39. Hogue-Angeletti, R.A.; Bradshaw, R.A. Nerve Growth Factors in Snake Venoms. In Snake Venoms; Lee, C.Y., Ed.; Springer: Berlin, Germany, 1979; pp. 276-294.
40. Dolle, J.-P.; Rezvan, A.; Allen, F.D.; Lazarovici, P.; Lelkes, P.I. Nerve growth factor-induced migration of endothelial cells. J. Pharmacol. Exp. Ther. 2005, 315, 1220-1227.
41. Lazarovici, P.; Marcinkiewicz, C.; Lelkes, P.I. Cross talk between the cardiovascular and nervous systems: Neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr. Pharm. Des. 2006, 12, 2609-2622.
42. Clark, E.; Brugge, J. Integrins and signal transduction pathways: The road taken. Science 1995, 268, 233-239.
43. Hood, J.D.; Cheresh, D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2, 91-100.
44. Liddington, R.C.; Ginsberg, M.H. Integrin activation takes shape. J. Cell Biol. 2002, 158, 833-839.
45. Schaller, M. Biochemical signals and biological response elicited by the focal adhesion kinase. Biochim. Biophys. Acta 2001, 1540, 1-21.
46. Giancotti, F.G.; Ruoslahti, E. Integrin signaling. Science 1999, 285, 1028-1033.
47. Stupack, D.G.; Cheresh, D.A. Get a ligand, get a life: Integrins, signaling and cell survival. J. Cell Sci. 2002, 115, 3729-3738.
48. Marcinkiewicz, C. Functional characteristic of snake venom disintegrins: Potential therapeutic implication. Curr. Pharm. Des. 2005, 11, 815-827.
49. Plow, E.F.; Haas, T.A.; Zhang, L.; Loftus, J.; Smith, J.W. Ligand binding to integrins. J. Biol. Chem. 2000, 275, 21785-21788.
50. Marcinkiewicz, C.; Calvete, J.J.; Marcinkiewicz, M.M.; Raida, M.; Vijay-Kumar, S.; Huang, Z.; Lobb, R.R.; Niewiarowski, S. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits alpha4 and alpha5 integrins in an RGD-independent manner. J. Biol. Chem. 1999, 274, 12468-12473.
51. Moreno-Murciano, M.P.; Monleón, D.; Calvete, J.J.; Celda, B.; Marcinkiewicz, C. Amino acid sequence and homology modeling of obtustatin, a novel non-RGD-containing short disintegrin isolated from the venom of Vipera lebetina obtuse. Protein Sci. 2003, 12, 366-371.
52. Brown, M.C.; Eble, J.A.; Calvete, J.J.; Marcinkiewicz, C. Structural requirements of KTS-disintegrins for inhibition of α1β1 integrin. Biochem. J. 2009, 417, 95-101.
53. Kallech-Ziri, O.; Luis, J.; Faljoun, Z.; Sabatier, J.-M.; Lehmann, M.; El Ayeb, M.; Marrakchi, N.; Loret, E. Structure function relationships of KTS disintegrins and design of antiangiogenic drugs Lett. Drug Des. Discov. 2010, 7, 36-40.
54. Staniszewska, I.; Walsh, E.M.; Rothman, V.L.; Gaathon, A.; Tuszynski, G.P.; Calvete, J.J.; Lazarovici, P.; Marcinkiewicz, C. Effect of VP12 and viperistatin on inhibition of collagen receptors: Dependent melanoma metastasis. Cancer Biol. Ther. 2009, 8, 1507-1516.
55. Horii, K.; Okuda, D.; Morita, T.; Mizuno, H. Crystal structure of EMS16 in complex with the integrin α2-I domain. J. Mol. Biol. 2004, 341, 519-527.
56. Eble, J.A.; Niland, S.; Bracht, T.; Mormann, M.; Peter-Katalinic, J.; Pohlentz, G.; Stetefeld, J. The α2β1integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule. FASEB J. 2009, 23, 2917-2927.
57. Morita, T. Structure-function relationship of C-type lectin-related proteins. Pathophysiol. Haemost. Thromb. 2005, 34, 156-159.
58. Arlinghaus, F.; Marcinkiewicz, C.; Lazarovici, P.; Eble, J.A. Snake Venoms Contain Important Anti-Thrombocit Antagonists Selectively Targeting Collagen α2β1. In Proceedings of the 33th World Congress of the International Society of Hematology, Jerusalem, Palestine, 10-10October 2010.
59. Walsh, E.M.; Marcinkiewicz, C. Non-RGD-containing snake venom disintegrins, functional and structural relations. Toxicon 2011, 58, 355-362.
60. Moroz, C. Vipera palestinae antivenin. Public Health Rev. 1998, 26, 233-236.
61. Moroz, C.; de Vries, A.; Goldblum, N. Preparation of an antivenin against Vipera palestinae venom with high antineurotoxic potency. Toxicon 1966, 4, 205-208.
62. Moroz, C.; Hahn, J.; de Vries, A. Neutralization of Vipera palestinae hemorrhagin by antibody fragments. Toxicon 1971, 9, 57-62.
63. Weinstein, S.A.; Dart, R.C.; Staples, A.; White, J. Envenomations: An overview of clinical toxinology for the primary care physician. Am. Fam. Physician 2009, 80, 793-802.
64. Williams, D.J.; Gutiérrez, J.-M.; Calvete, J.J.; Wüster, W.; Ratanabanangkoon, K.; Paiva, O.; Brown, N.I.; Casewell, N.R.; Harrison, R.A.; Rowley, P.D.; O'Shea, M.; Jensen, S.D.; Winkel, K.D.; Warrell, D.A. Ending the drought: New strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. J. Proteomics 2011, 74, 1735-1767.